Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

PTC Therapeutics Inc (NASDAQ:PTCT)

During the Trading Day
38.03 +0.19 / +0.50%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
38.03 0.00 / 0.00%
Volume: 4.9K
Health Technology

Company Description

PTC Therapeutics, Inc. is a biopharmaceutical company, which is focused on the discovery, development and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. The company's preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. The company's lead product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Contact Information

PTC Therapeutics, Inc.
100 Corporate Court
South Plainfield New Jersey 07080-2449
P:(908) 222-7000
Investor Relations:



Mutual fund holders61.40%
Other institutional37.54%
Individual stakeholders23.52%

Top Executives

Stuart W. PeltzChief Executive Officer & Director
Neil Gregory AlmsteadExecutive VP-Research, Operations & Technology
Shane William Charles KovacsCFO & Head-Corporate Development
Robert Jay SpiegelChief Medical Officer
Mark Elliott BouldingSecretary, Chief Legal Officer & Executive VP